# Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients

> **NCT01040780** · PHASE3 · COMPLETED · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 399 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Icotinib
- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT01040780
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2010-03
- **Final completion:** 2011-12
- **Target enrollment:** 399 (ACTUAL)
- **Last updated:** 2014-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01040780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01040780, "Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01040780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*